PIRS - Pieris Pharmaceuticals Inc Stock Price, Fair Value and News

$13.04-0.46 (-3.41%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PIRS Price Action

Last 7 days

3.7%


Last 30 days

8.7%


Last 90 days

-24.6%


Trailing 12 Months

-9.4%

PIRS Stock Price

Mar'24Jun'24Sep'24Dec'245101520
$13.04

PIRS RSI Chart

MayJunJulAugSepOctNovDec2025020406080100

PIRS Valuation

Market Cap

17.2M

Price/Earnings (Trailing)

1.66

Price/Sales (Trailing)

0.5

EV/EBITDA

-0.04

Price/Free Cashflow

-2.19

PIRS Price/Sales (Trailing)

202220232024051015

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PIRS Fundamentals

PIRS Revenue

Revenue (TTM)

42.9M

201420162018202020222024010M20M30M40M50M60M

PIRS Earnings

Earnings (TTM)

10.4M

Earnings Growth (Yr)

-139.23%

Earnings Growth (Qtr)

-88.72%

201420162018202020222024-60M-40M-20M020M

PIRS Profitability

EBT Margin

-106.71%

Return on Equity

63.79%

Return on Assets

63.58%

Free Cashflow Yield

-45.66%

PIRS Investor Care

Shares Dilution (1Y)

6.85%

Diluted EPS (TTM)

5.35

Revenue Breakdown

As of: Sep 30, 2024
201620182020202205M10M15M20M
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20142016201820202022010M20M30M40M50M60M
Net sales
YearQ1Q2Q3Q4
20240000
202316.7M33.3M47.5M42.9M
202227.0M27.1M28.5M25.9M
202131.7M23.7M24.9M31.4M
202051.0M56.9M44.7M29.3M
201933.5M27.1M33.9M46.3M
201828.1M37.9M42.3M29.1M
20175.9M6.7M9.8M25.3M
20164.0M4.9M5.2M5.8M
20154.2M3.7M4.1M2.9M
201410.7M8.9M7.1M5.4M
20130011.9M12.4M
201200011.4M
Get all data in R, Python etc through our Historical Stock Data APIs
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEpieris.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES127

Pieris Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Pieris Pharmaceuticals Inc? What does PIRS stand for in stocks?

PIRS is the stock ticker symbol of Pieris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pieris Pharmaceuticals Inc (PIRS)?

As of Fri Jan 31 2025, market cap of Pieris Pharmaceuticals Inc is 17.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PIRS stock?

You can check PIRS's fair value in chart for subscribers.

Is Pieris Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PIRS is over valued or under valued. Whether Pieris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Pieris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PIRS.

What is Pieris Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 31 2025, PIRS's PE ratio (Price to Earnings) is 1.66 and Price to Sales (PS) ratio is 0.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PIRS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pieris Pharmaceuticals Inc's stock?

In the past 10 years, Pieris Pharmaceuticals Inc has provided -0.248 (multiply by 100 for percentage) rate of return.